Drug intelligence / Profile preview

LG1188

Development stage: Unknown
Lead developer: University of Wisconsin–Madison
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

LG1188: sourced facts only. name: "Among them, PROTAC LG1188 was identified as a potent and selective FGFR1 degrader." [PMID:36096343]; target: "Among them, PROTAC LG1188 was identified as a potent and selective FGFR1 degrader." [PMID:36096343]; developer: "Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA." [PMID:36096343]; modality: "Among them, PROTAC LG1188 was identified as a potent and selective FGFR1 degrader." [PMID:36096343]

Targets

FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on LG1188.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LG1188.